TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01464242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine antimonate
Description: Glucantime® 20mg/kg/day IM daily for 20 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meglumine antimonate
Description: Glucantime® 20mg/kg/day IM daily for 20 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 400mg orally 3 times a day for 20 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg orally 3 times a day for 20 days
Study: NCT01401465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide
Description: 74 mcg ciclesonide nasal aerosol once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone
Description: 200 mcg mometasone aqueous nasal spray once daily
Study: NCT03079349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Education
Description: All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Education
Description: All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Intervention
Description: All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Intervention
Description: All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
Study: NCT01836211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast strategy
Description: High sensitivity troponin T followed by computed coronary tomography angiography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care strategy
Description: Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
Study: NCT02000453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 400mg
Description: White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
Study: NCT01846117

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: secoisolariciresinol diglucoside, vitamin D
Description: SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: secoisolariciresinol diglucoside, vitamin D
Description: SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
Study: NCT02522403

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Lever Laser acupuncture
Description: The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
Study: NCT04019184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Alanyl/L-Glutamine
Description: Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
Study: NCT02206620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Study: NCT01720199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diario della Salute (DDS)
Description: DDS is composed by~1. tools for children and their parents on health and social and emotional well-being issues:~   1. a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~  2. a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~2. five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers.
Study: NCT00608192

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Testing, Education, & Counseling (TEC)
Description: Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hepatitis Care Coordination (HCC)
Description: HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
Study: NCT00916136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Traction
Description: Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Traction
Description: Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
Study: NCT01698437

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive intervention with focused ultrasound (ExAblate 4000)
Description: Non-invasive brain intervention using MR-guided focused ultrasound
Study: NCT03516084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-2306(nirapairb)
Description: The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
Study: NCT03173053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfamethoxazole/trimethoprim
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fusidic Acid
Description: tablet or ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: tablet
Study: NCT02121093

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vibration
Study: NCT01042314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Tablets, Oral, 5 mg, Once Daily, Days 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Capsule, Oral, 125 mg, Once Daily, Days 15-28
Study: NCT04304560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: inhibitor of sodium-glucose cotransporter 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Similar Placebo oral tablet
Study: NCT01697111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP(BAY86-5300)
Description: One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One tablet (no active ingredient) / day and one tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day, for the first 24 weeks and the later 28 weeks, respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest
Description: Dienogest 1mg twice a day (bid)
Study: NCT03239457

Intervention type: BIOLOGICAL
Intervention: Heberprot P
Description: 75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
Study: NCT01141530

Intervention type: OTHER
Intervention: No intervention
Description: Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
Study: NCT02781441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Question prompt list (QPL)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Question prompt list (QPL)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education brochure of Groupe Français des Myélodysplasies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education brochure of Groupe Français des Myélodysplasies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education brochure of Groupe Français des Myélodysplasies
Study: NCT01621178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: Administered SC
Study: NCT04203472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Budesonid or budesonide/fomoterol administered by DPI
Description: Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Budesonid or budesonide/fomoterol administered by MDI
Description: Budiair 200 mcg or Atimos 12 mcg
Study: NCT00831389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop
Description: Insulin pump controlled by closed loop unit and algorithm
Study: NCT03319641

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT scan
Description: perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
Study: NCT02070653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01115907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom SOLO Stentless Heart Valve
Description: Freedom SOLO Stentless Heart Valve
Study: NCT01889992

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Description: 1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short \& long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 \>/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: 1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short \& long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 \>/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography with IVUS
Description: Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography with IVUS
Description: Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart.
Study: NCT04306705

Intervention type: PROCEDURE
Intervention: Continuous renal replacement therapy
Description: Catheter insertion site is femoral vein.
Study: NCT03278769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung protective ventilator settings
Description: Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
Study: NCT01889992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Allograft Remodeling
Description: A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Allograft Remodeling
Description: A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M-TOR Immunosuppression
Description: Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Biopsy C4D stain
Description: A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Mechanism of M-TOR
Description: To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
Study: NCT02969070

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LopiGLIK™ therapy
Description: 4 weeks of LopiGLIK™ therapy 1 capsule/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Armolipid Plus® therapy
Description: 4 weeks of Armolipid Plus® therapy 1 capsule/day
Study: NCT03669796

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine protein hydrolysate (mph)
Description: Marine (Cod) protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Maltodextrin/Casein
Study: NCT04554303

Intervention type: DRUG
Intervention: S-amlodipine 2.5mg
Description: Oral administration, 1 tablet per day
Study: NCT02606448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivicaine was used in all femoral nerve blocks
Study: NCT04554303

Intervention type: DRUG
Intervention: Amlodipine 5mg
Description: Oral administration, 1 tablet per day
Study: NCT01854684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temoporfin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo intraoperative PDT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02092441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol prep pad group
Description: Subjects inhale scent of alcohol pad

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline prep pad
Description: Subjects inhale scent of placebo (normal saline) pads
Study: NCT02156492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally.
Study: NCT01854684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02156492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally.
Study: NCT04047446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 133 MG Per 10 ML Injection
Description: 10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected
Study: NCT04156139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC
Description: The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPPV
Description: The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPPV
Description: The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
Study: NCT01020357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate injection
Description: Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: normal saline
Study: NCT03271866

Intervention type: DRUG
Group type: OTHER
Intervention: metformin
Description: metformin 1500mg per day